Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Weill Cornell Medicine

Neither a doctor nor a teaching hospital

Research payments

$5,676,431

726 payments

Through program year 2025, Weill Cornell Medicine is reported as receiving $5,676,431 in research payments, across 726 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $2,206,270 304
2024 Research $1,542,334 59
2023 Research $574,512 26
2022 Research $611,721 24
2021 Research $322,977 195
2020 Research $283,081 52
2019 Research $135,537 66

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $1,396,467 72 payments
  2. AstraZeneca Pharmaceuticals LP $1,269,890 22 payments
  3. Incyte Corporation $862,119 271 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $322,371 6 payments
  5. Ipsen Biopharmaceuticals, Inc $207,750 1 payment
  6. Celgene Corporation $198,219 7 payments
  7. Epizyme, Inc., $150,243 28 payments
  8. Eisai Inc. $119,760 42 payments
  9. Insmed, Inc. $116,904 16 payments
  10. Servier Pharmaceuticals LLC $115,202 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation $365,884 129 payments
  2. A Single Arm Phase II Study with Safety Run-in of Peptide Receptor Radionuclide Therapy (PRRT) in Combination with Immunotherapy for Patients with Merkel Cell Cancer (HCRN-MCC20-443; iPRRT Study) $332,160 1 payment
  3. V503-049 A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent infection with HPV Types 16, 18, 31, 33, 45, 52, or 58 in adult males, 20 to 45 years of age $315,910 8 payments
  4. STUDY NAME#A Single Arm Phase II Study with Safety Run-in of Peptide Receptor Radionuclide Therapy PRRT in Combination with Immunotherapy for Patients with Merkel Cell Cancer HCRN-MCC20-443 iPRRT Study $268,095 1 payment
  5. Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men living with HIV $247,566 3 payments
  6. A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis $243,241 73 payments
  7. A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy $219,099 2 payments
  8. A Modular Phase I/II, Open-label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD9829 as Monotherapy or in Combination in Patients with CD123-positive Hematological Malignancies $213,345 2 payments
  9. A Phase II trial of tazemetostat plus mosunetuzumab in untreated follicular lymphoma $207,750 1 payment
  10. Sra WCM - Tumor-On-Vascularnet Platform for Enabling Immune Cancer Targeting $200,463 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record